{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:11:34Z","timestamp":1789071094755,"version":"build-2803163510"},"reference-count":124,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011302","name":"Children's Hospital Foundation","doi-asserted-by":"publisher","award":["RPC00095"],"award-info":[{"award-number":["RPC00095"]}],"id":[{"id":"10.13039\/100011302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Cytomegalovirus (CMV) is a ubiquitous virus which causes a mild illness in healthy individuals. In immunocompromised individuals, such as children receiving haematopoietic stem cell transplantation, CMV can reactivate, causing serious disease and increasing the risk of death. CMV can be effectively treated with antiviral drugs, but antiviral resistance is an increasingly common complication. Available therapies are associated with adverse effects such as bone marrow suppression and renal impairment, making the choice of appropriate treatment challenging. New agents are emerging and require evaluation in children to establish their role. This review will discuss established and emerging diagnostic tools and treatment options for CMV, including antiviral resistant CMV, in children undergoing haematopoietic stem cell transplant.<\/jats:p>","DOI":"10.3389\/fped.2023.1180392","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T09:51:17Z","timestamp":1685613077000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Cytomegalovirus in children undergoing haematopoietic stem cell transplantation: a diagnostic and therapeutic approach to antiviral resistance"],"prefix":"10.3389","volume":"11","author":[{"given":"Jocelyn","family":"Hume","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kym","family":"Lowry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia E.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Whiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D.","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1073\/pnas.91.7.2384","article-title":"Working parents: the impact of day care and breast-feeding on cytomegalovirus infections in offspring","volume":"91","author":"Stagno","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1128\/CVI.00203-06","article-title":"National serosurvey of cytomegalovirus in Australia","volume":"13","author":"Seale","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","article-title":"CMV Reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia","volume":"122","author":"Green","year":"2013","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/sj.bmt.1705699","article-title":"Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies","volume":"40","author":"Ozdemir","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"B6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/cid\/cix259","article-title":"Risk factors and outcomes of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients","volume":"65","author":"Fisher","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D\u2019Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3855\/jidc.2947","article-title":"Cytomegalovirus reactivation following hematopoietic stem cell transplantation","volume":"7","author":"Sharma","year":"2013","journal-title":"J Infect Dev Ctries"},{"key":"B9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ijid.2016.03.025","article-title":"Herpesvirus infections in hematopoietic stem cell transplant recipients seropositive for human cytomegalovirus before transplantation","volume":"46","author":"Fan","year":"2016","journal-title":"Int J Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/cid\/ciu364","article-title":"Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation","volume":"59","author":"Ljungman","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e14172","DOI":"10.1097\/MD.0000000000014172","article-title":"Factors associated with cytomegalovirus infection in children undergoing allogeneic hematopoietic stem-cell transplantation","volume":"98","author":"Jaing","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.bbmt.2016.04.004","article-title":"Cytomegalovirus infection in pediatric hematopoietic stem cell transplantation: risk factors for primary infection and cases of recurrent and late infection at a single center","volume":"22","author":"Rowe","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1399-3062.2010.00504.x","article-title":"Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy","volume":"12","author":"George","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/bmt.2012.221","article-title":"Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients","volume":"48","author":"Hiwarkar","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e13580","DOI":"10.1111\/tid.13580","article-title":"Epidemiology and outcome for viremia in children undergoing bone marrow transplant: a retrospective cohort study","volume":"23","author":"Silcock","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/tid.12309","article-title":"Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study","volume":"16","author":"Marchesi","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5500\/wjt.v5.i3.129","article-title":"Cytomegalovirus reactivation after autologous stem cell transplantation in myeloma and lymphoma patients: a single-center study","volume":"5","author":"Marchesi","year":"2015","journal-title":"World J Transplant"},{"key":"B18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00430-008-0094-1","article-title":"Hematopoietic stem cell transplantation with latently infected donors does not transmit virus to immunocompromised recipients in the murine model of cytomegalovirus infection","volume":"197","author":"Seckert","year":"2008","journal-title":"Med Microbiol Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e13458","DOI":"10.1111\/petr.13458","article-title":"Management and prevention of cytomegalovirus infection in paediatric hematopoietic stem cell transplant (HSCT) recipients: a binational survey","volume":"23","author":"Al Yazidi","year":"2019","journal-title":"Pediatr Transplant"},{"key":"B20","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jcyt.2021.10.002","article-title":"Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients","volume":"24","author":"Camacho-Bydume","year":"2022","journal-title":"Cytotherapy"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/transplantology2010002","article-title":"Management of herpesvirus infections in hematopoietic cell transplant recipients","volume":"2","author":"Styczynski","year":"2021","journal-title":"Transplantology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13104-017-2532-x","article-title":"Very-late-onset cytomegalovirus disease: a case-report and review of the literature","volume":"10","author":"Burgan","year":"2017","journal-title":"BMC Res Notes"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1097\/01.tp.0000226071.12562.1a","article-title":"Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis","volume":"81","author":"Limaye","year":"2006","journal-title":"Transplantation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1086\/519941","article-title":"Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients","volume":"45","author":"Li","year":"2007","journal-title":"Clin Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1399-3062.2010.00584.x","article-title":"Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients","volume":"13","author":"Iwasenko","year":"2011","journal-title":"Transpl Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1600-6143.2008.02513.x","article-title":"Interlaboratory comparison of cytomegalovirus viral load assays","volume":"9","author":"Pang","year":"2009","journal-title":"Am J Transplant"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1128\/JCM.02036-13","article-title":"Multicenter evaluation of a commercial cytomegalovirus quantitative standard: effects of commutability on interlaboratory concordance","volume":"51","author":"Hayden","year":"2013","journal-title":"J Clin Microbiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1128\/AAC.49.4.1580-1583.2005","article-title":"Early selection of a new UL97 mutant with a severe defect of ganciclovir phosphorylation after valaciclovir prophylaxis and short-term ganciclovir therapy in a renal transplant recipient","volume":"49","author":"Hantz","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"B30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.antiviral.2012.05.013","article-title":"Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo","volume":"95","author":"Chou","year":"2012","journal-title":"Antiviral Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0042-6822(83)90339-2","article-title":"Characterization of human cytomegalovirus-induced DNA polymerase and the associated 3\u2032-to-5\u2032, exonuclease","volume":"124","author":"Nishiyama","year":"1983","journal-title":"Virology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"771978","DOI":"10.3389\/fmicb.2022.771978","article-title":"Analysis of novel drug-resistant human cytomegalovirus DNA polymerase mutations reveals the role of a DNA-binding loop in phosphonoformic acid resistance","volume":"13","author":"Park","year":"2022","journal-title":"Front Microbiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e00922","DOI":"10.1128\/AAC.00922-18","article-title":"New locus of drug resistance in the human cytomegalovirus UL56 gene revealed by in vitro exposure to letermovir and ganciclovir","volume":"62","author":"Chou","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1128\/JCM.01605-13","article-title":"Detection of cytomegalovirus drug resistance mutations by next-generation sequencing","volume":"51","author":"Sahoo","year":"2013","journal-title":"J Clin Microbiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jcv.2014.07.008","article-title":"Detecting human cytomegalovirus drug resistant mutations and monitoring the emergence of resistant strains using real-time PCR","volume":"61","author":"Volfova","year":"2014","journal-title":"J Clin Virol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jcv.2007.07.003","article-title":"Emergence and persistence of multiple antiviral-resistant CMV strains in a highly immunocompromised child","volume":"40","author":"Iwasenko","year":"2007","journal-title":"J Clin Virol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0140-6736(00)02607-6","article-title":"Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants","volume":"356","author":"Limaye","year":"2000","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1128\/AAC.00561-13","article-title":"Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens","volume":"58","author":"Minces","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1093\/jac\/dkq368","article-title":"Drug-resistant cytomegalovirus in transplant recipients: a French cohort study","volume":"65","author":"Hantz","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"B41","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1399-0012.2007.00761.x","article-title":"Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes","volume":"22","author":"Eid","year":"2008","journal-title":"Clin Transplant"},{"key":"B42","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/jac\/dkn521","article-title":"Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus","volume":"63","author":"Allice","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"B43","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/j.1399-3062.2007.00235.x","article-title":"Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation","volume":"9","author":"Almyroudis","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1034\/j.1399-3062.2002.t01-1-02008.x","article-title":"Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection","volume":"4","author":"Isada","year":"2002","journal-title":"Transpl Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1111\/ajt.15135","article-title":"Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection","volume":"18","author":"Cherrier","year":"2018","journal-title":"Am J Transplant"},{"key":"B46","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12879-019-4016-1","article-title":"Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient","volume":"19","author":"Jung","year":"2019","journal-title":"BMC Infect Dis"},{"key":"B47","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1399-3062.2010.00550.x","article-title":"Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients","volume":"12","author":"Avery","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2042-4280-1-4","article-title":"The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein","volume":"1","author":"Shannon-Lowe","year":"2010","journal-title":"Herpesviridae"},{"key":"B49","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1093\/infdis\/jiaa462","article-title":"Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection","volume":"226","author":"Chou","year":"2022","journal-title":"J Infect Dis"},{"key":"B50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/jmv.20150","article-title":"Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations","volume":"74","author":"Scott","year":"2004","journal-title":"J Med Virol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e0219701","DOI":"10.1371\/journal.pone.0219701","article-title":"Improvement in detecting cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance using next generation sequencing","volume":"14","author":"Lopez-Aladid","year":"2019","journal-title":"PLoS One"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3389\/fmicb.2016.01317","article-title":"Detection of low frequency multi-drug resistance and novel putative maribavir resistance in immunocompromised pediatric patients with cytomegalovirus","volume":"7","author":"Houldcroft","year":"2016","journal-title":"Front Microbiol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1128\/AAC.00802-10","article-title":"Improved detection of mutated human cytomegalovirus UL97 by pyrosequencing","volume":"54","author":"Schindele","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"B54","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jcv.2016.04.017","article-title":"Contribution of next generation sequencing to early detection of cytomegalovirus UL97 emerging mutants and viral subpopulations analysis in kidney transplant recipients","volume":"80","author":"Garrigue","year":"2016","journal-title":"J Clin Virol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1093\/infdis\/jiw064","article-title":"Utility of the enzyme-linked immunospot interferon-gamma-release assay to predict the risk of cytomegalovirus infection in hematopoietic cell transplant recipients","volume":"213","author":"Nesher","year":"2016","journal-title":"J Infect Dis"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1093\/infdis\/jix192","article-title":"Identifying cytomegalovirus complications using the quantiferon-CMV assay after allogeneic hematopoietic stem cell transplantation","volume":"215","author":"Yong","year":"2017","journal-title":"J Infect Dis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1093\/cid\/ciz1210","article-title":"Cytomegalovirus (CMV) cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: the REACT study","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1128\/JCM.00803-14","article-title":"Clinical utility of droplet digital PCR for human cytomegalovirus","volume":"52","author":"Sedlak","year":"2014","journal-title":"J Clin Microbiol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"113864","DOI":"10.1016\/j.jviromet.2020.113864","article-title":"Digital PCR method for detection and quantification of specific antimicrobial drug-resistance mutations in human cytomegalovirus","volume":"281","author":"Bogozalec Kosir","year":"2020","journal-title":"J Virol Methods"},{"key":"B60","doi-asserted-by":"publisher","first-page":"111831","DOI":"10.1016\/j.envres.2021.111831","article-title":"Discrimination of non-infectious SARS-CoV-2 particles from fomites by viability RT-qPCR","volume":"203","author":"Cuevas-Ferrando","year":"2022","journal-title":"Environ Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cmi.2021.08.009","article-title":"Diagnostic usefulness of subgenomic RNA detection of viable SARS-CoV-2 in patients with COVID-19","volume":"28","author":"Kim","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1099\/vir.0.80910-0","article-title":"Murine cytomegalovirus resistant to antivirals has genetic correlates with human cytomegalovirus","volume":"86","author":"Scott","year":"2005","journal-title":"J Gen Virol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0166-3542(97)00013-2","article-title":"Metabolism of ganciclovir and cidofovir in cells infected with drug-resistant and wild-type strains of murine cytomegalovirus","volume":"35","author":"Okleberry","year":"1997","journal-title":"Antiviral Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"10729","DOI":"10.1128\/JVI.74.22.10729-10736.2000","article-title":"Comparison between human cytomegalovirus pUL97 and murine cytomegalovirus (MCMV) pM97 expressed by MCMV and vaccinia virus: pM97 does not confer ganciclovir sensitivity","volume":"74","author":"Wagner","year":"2000","journal-title":"J Virol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e1006299","DOI":"10.1371\/journal.ppat.1006299","article-title":"Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection","volume":"13","author":"Rose","year":"2017","journal-title":"PLoS Pathog"},{"key":"B66","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.csbj.2015.01.003","article-title":"Antiviral drug- and multidrug resistance in cytomegalovirus infected SCT patients","volume":"13","author":"Gohring","year":"2015","journal-title":"Comput Struct Biotechnol J"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/14740338.2019.1662787","article-title":"Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation","volume":"18","author":"El Helou","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1111\/j.1600-6143.2005.00866.x","article-title":"A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients","volume":"5","author":"Humar","year":"2005","journal-title":"Am J Transplant"},{"key":"B69","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1517\/17425255.2015.988139","article-title":"Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection","volume":"11","author":"Stockmann","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"ofab639","DOI":"10.1093\/ofid\/ofab639","article-title":"Risk factors for CMV viremia and treatment-associated adverse events among pediatric hematopoietic stem cell transplant recipients","volume":"9","author":"Heston","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"B71","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/INF.0000000000001595","article-title":"Valganciclovir dosing for cytomegalovirus prophylaxis in pediatric solid-organ transplant recipients: a prospective pharmacokinetic study","volume":"36","author":"Peled","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"B72","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0163-7258(89)90097-1","article-title":"Antiviral effects of phosphonoformate (PFA, foscarnet sodium)","volume":"40","author":"Oberg","year":"1989","journal-title":"Pharmacol Ther"},{"key":"B73","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/pbc.21043","article-title":"A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients","volume":"49","author":"Shereck","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/323464a0","article-title":"A novel selective broad-spectrum anti-DNA virus agent","volume":"323","author":"De Clercq","year":"1986","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1128\/AAC.04348-14","article-title":"Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients","volume":"59","author":"Caruso Brown","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"B76","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e13521","DOI":"10.1111\/tid.13521","article-title":"Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection","volume":"23","author":"Mehta Steinke","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"B78","year":""},{"key":"B79","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1128\/jvi.68.2.1040-1051.1994","article-title":"Human cytomegalovirus DNA replicates after early circularization by concatemer formation, and inversion occurs within the concatemer","volume":"68","author":"McVoy","year":"1994","journal-title":"J Virol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1177\/135965350801300504","article-title":"Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity","volume":"13","author":"Champier","year":"2008","journal-title":"Antivir Ther"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2017.10.019","article-title":"A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","volume":"148","author":"Chou","year":"2017","journal-title":"Antiviral Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1128\/AAC.05908-11","article-title":"In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses","volume":"56","author":"Marschall","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/cpdd.388","article-title":"Pharmacokinetics and safety of letermovir coadministered with cyclosporine A or tacrolimus in healthy subjects","volume":"7","author":"Kropeit","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"B85","doi-asserted-by":"publisher","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"740079","DOI":"10.3389\/fonc.2021.740079","article-title":"Letermovir prophylaxis for cytomegalovirus infection in allogeneic stem cell transplantation: a real-world experience","volume":"11","author":"Martino","year":"2021","journal-title":"Front Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/cid\/ciab298","article-title":"Refractory and resistant cytomegalovirus after hematopoietic cell transplant in the letermovir primary prophylaxis era","volume":"73","author":"Sassine","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00277-020-04362-2","article-title":"Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data","volume":"100","author":"Derigs","year":"2021","journal-title":"Ann Hematol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jiac.2022.05.019","article-title":"Real-world efficacy of letermovir prophylaxis for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation: a single-center retrospective analysis","volume":"28","author":"Yoshimura","year":"2022","journal-title":"J Infect Chemother"},{"key":"B91","doi-asserted-by":"publisher","first-page":"62 e1","DOI":"10.1016\/j.jtct.2022.10.005","article-title":"Letermovir as cytomegalovirus prophylaxis in a pediatric cohort: a retrospective analysis","volume":"29","author":"Kuhn","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B92","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/jpids\/piac017","article-title":"Letermovir for cytomegalovirus prevention in adolescent patients following hematopoietic cell transplantation","volume":"11","author":"Daukshus","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2147\/IDR.S296927","article-title":"Off-label use of letermovir as preemptive anti-cytomegalovirus therapy in a pediatric allogeneic peripheral blood stem cell transplant","volume":"14","author":"Chiereghin","year":"2021","journal-title":"Infect Drug Resist"},{"key":"B94","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40272-022-00547-6","article-title":"Letermovir for prophylaxis and pre-emptive therapy of cytomegalovirus infection in paediatric allogeneic haematopoietic cell transplant patients","volume":"25","author":"Korholz","year":"2023","journal-title":"Paediatr Drugs"},{"key":"B95","year":""},{"key":"B96","year":""},{"key":"B97","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.antiviral.2018.07.013","article-title":"Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus","volume":"157","author":"Chou","year":"2018","journal-title":"Antiviral Res"},{"key":"B98","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N Engl J Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1537-2995.2010.02940.x","article-title":"Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation","volume":"51","author":"Schmitt","year":"2011","journal-title":"Transfusion"},{"key":"B101","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/16078454.2019.1710945","article-title":"Donor CMV-specific cytotoxic T lymphocytes successfully treated drug-resistant cytomegalovirus encephalitis after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Ke","year":"2020","journal-title":"Hematology"},{"key":"B102","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1158\/1078-0432.CCR-22-2415","article-title":"Posoleucel, an allogeneic, off-the-shelf multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting","volume":"29","author":"Pfeiffer","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","first-page":"7437","DOI":"10.1016\/j.vaccine.2018.02.089","article-title":"Vaccination against the human cytomegalovirus","volume":"37","author":"Plotkin","year":"2019","journal-title":"Vaccine"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.vaccine.2018.01.029","article-title":"Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity","volume":"36","author":"John","year":"2018","journal-title":"Vaccine"},{"key":"B105","year":""},{"key":"B106","doi-asserted-by":"publisher","first-page":"e1010403","DOI":"10.1371\/journal.ppat.1010403","article-title":"A bivalent CMV vaccine formulated with human compatible TLR9 agonist CpG1018 elicits potent cellular and humoral immunity in HLA expressing mice","volume":"18","author":"Dasari","year":"2022","journal-title":"PLoS Pathog"},{"key":"B107","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1159\/000053979","article-title":"Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide","volume":"42","author":"Waldman","year":"1999","journal-title":"Intervirology"},{"key":"B108","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/ndtplus\/sfp004","article-title":"Leflunomide: a treatment option for ganciclovir-resistant cytomegalovirus infection after renal transplantation","volume":"2","author":"Andrassy","year":"2009","journal-title":"NDT Plus"},{"key":"B109","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/TP.0b013e3181e94106","article-title":"Utility of leflunomide in the treatment of complex cytomegalovirus syndromes","volume":"90","author":"Avery","year":"2010","journal-title":"Transplantation"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/j.bbmt.2019.04.028","article-title":"Use of leflunomide for treatment of cytomegalovirus infection in recipients of allogeneic stem cell transplant","volume":"25","author":"Gokarn","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B111","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.antiviral.2013.10.014","article-title":"Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus","volume":"101","author":"Germi","year":"2014","journal-title":"Antiviral Res"},{"key":"B112","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.antiviral.2011.03.184","article-title":"Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation","volume":"90","author":"Wolf","year":"2011","journal-title":"Antiviral Res"},{"key":"B113","doi-asserted-by":"publisher","first-page":"15013","DOI":"10.1074\/jbc.RA120.014116","article-title":"Artemisinins target the intermediate filament protein vimentin for human cytomegalovirus inhibition","volume":"295","author":"Roy","year":"2020","journal-title":"J Biol Chem"},{"key":"B114","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.antiviral.2005.10.003","article-title":"The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo","volume":"69","author":"Kaptein","year":"2006","journal-title":"Antiviral Res"},{"key":"B115","doi-asserted-by":"publisher","first-page":"104711","DOI":"10.1016\/j.antiviral.2020.104711","article-title":"Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance","volume":"176","author":"Chou","year":"2020","journal-title":"Antiviral Res"},{"key":"B116","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"B117","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/MOT.0000000000000541","article-title":"Drug-resistant cytomegalovirus: clinical implications of specific mutations","volume":"23","author":"Razonable","year":"2018","journal-title":"Curr Opin Organ Transplant"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/infdis\/jiz642","article-title":"De novo genotypic heterogeneity in the UL56 region in cytomegalovirus-infected tissues: implications for primary letermovir resistance","volume":"221","author":"Jo","year":"2020","journal-title":"J Infect Dis"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/infdis\/jiz577","article-title":"Letermovir resistance analysis in a clinical trial of cytomegalovirus prophylaxis for hematopoietic stem cell transplant recipients","volume":"221","author":"Douglas","year":"2020","journal-title":"J Infect Dis"},{"key":"B120","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1093\/jac\/dkz196","article-title":"Antiviral-resistant cytomegalovirus infections in solid organ transplantation in The Netherlands","volume":"74","author":"Van Leer Buter","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"B121","doi-asserted-by":"publisher","first-page":"104549","DOI":"10.1016\/j.antiviral.2019.104549","article-title":"In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","volume":"169","author":"Komatsu","year":"2019","journal-title":"Antiviral Res"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1093\/infdis\/jiac349","article-title":"Genotypic and phenotypic study of antiviral resistance mutations in refractory cytomegalovirus infection","volume":"226","author":"Santos Bravo","year":"2022","journal-title":"J Infect Dis"},{"key":"B123","doi-asserted-by":"publisher","first-page":"105361","DOI":"10.1016\/j.antiviral.2022.105361","article-title":"First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure","volume":"204","author":"Muller","year":"2022","journal-title":"Antiviral Res"},{"key":"B124","doi-asserted-by":"publisher","first-page":"105139","DOI":"10.1016\/j.antiviral.2021.105139","article-title":"Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing","volume":"193","author":"Chou","year":"2021","journal-title":"Antiviral Res"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1180392\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T09:51:20Z","timestamp":1685613080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1180392\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":124,"alternative-id":["10.3389\/fped.2023.1180392"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1180392","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"article-number":"1180392"}}